

Investor update

**Ipsen's financial communication nominated to the
"2009 Trophy of the Best Investor Relations" of Euronext**

Paris (France), 17 December 2009 - Ipsen (Euronext: FR0010259150; IPN) announces today it has been awarded to the "2009 Trophy of the best investor relations of the year" for the quality of its financial communication in 2009. Ipsen's investor relations were nominated second besides Michelin and Seb. The prize awarded on 14 December 2009 is based on a survey carried out by IR Intelligence to a selection of financial analysts and fund managers in France, members of *Société Française des Analystes Financiers* (SFAF) that assessed all companies listed on the French market place Euronext.

David Schilansky, Investor Relations and Financial Officer of Ipsen said: *"We are very delighted to have been awarded this distinction, a "quality label", which recognizes the way Ipsen thrives for transparency and reliability in its continuous dialogue with shareholders and investors since its IPO in December 2005."*

About the prize

The forum « Investor Relations and Financial Communication » is sponsored by CLIFF (*Association Française des Investor Relations*), MiddleNext, SFAF (*Société Française des Analystes Financiers*), l'IFA (*l'Institut Français des Administrateurs*), l'AFG (*l'Association Française de la Gestion Financière*) and NYSE EURONEXT. The jury was chaired by Jean-Paul Pierret (Dexia) and included also: Roland Laskine (*Journal des Finances*), Gaël Faijean (SFAF and IDMidcaps), Valentine Bonnet (AFG), Nicole Micheletti (ex-CLIFF and Essilor), François Houssin (NYSE Euronext), Alain Martel (IFA) and Nicolas Raynier (IR•intelligence).

About Ipsen

Ipsen is an innovation-driven global specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was about €183 million, close to 19% of consolidated sales, which amounted to €971 million while total revenues exceeded €1 billion. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipsen.com.

For further information:

Media

Didier Véron

Director, Public Affairs and Corporate Communications

Tel.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

E-mail: didier.veron@ipsen.com

Financial Community

David Schilansky

Investor Relations and Financial Officer

Tel.: +33 (0)1 58 33 51 30

Fax: +33 (0)1 58 33 50 63

E-mail: david.schilansky@ipsen.com

Pierre Kemula

Investor Relations Manager

Tel.: +33 (0)1 58 33 60 08

Fax: +33 (0)1 58 33 50 63

E-mail: pierre.kemula@ipsen.com